Matthew Jenner

Southampton Hospital — United States

Medicine · Health Sciences

37h-index5.0kcitations198works2.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(169), Protein Degradation and Inhibitors(88), Cancer Treatment and Pharmacology(51), Peptidase Inhibition and Analysis(42), Histone Deacetylase Inhibitors Research(16)

Publications196 total

Randomized phase II dose optimization study of inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)
Blood·2025Open Access
Double hit ultra-high risk myeloma treated with isatuximab, bortezomib, lenalidomide, dexamethasone and cyclophosphamide (Isa-VRDc) induction and isa-VRD consolidation: Initial results of the UK myeloma research alliance (UKMRA)  RADAR trial in newly diagnosed transplant eligible patients
Blood·2025
Is IMWG frailty-score-adjusted dosing the right approach to improve toxicity and outcomes in FRAIL patients? Results from the UK-MRA FiTNEss trial in newly diagnosed myeloma patients ineligible for ASCT.
Blood·2025
Can a patient questionnaire (VRAT) reduce the need for ocular examinations with less frequent belantamab mafodotin combined with bortezomib and dexamethasone? the ukmra prommise d trial
Blood·2025
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial
The Lancet Haematology·2025· 1 cited
Management of relapsed multiple myeloma: A British Society of Haematology and UK Myeloma Society guideline
British Journal of Haematology·2025· 1 cited
<scp>NGS</scp> ‐based targeted sequencing guides risk‐adapted and molecularly targeted therapy decisions in multiple myeloma
British Journal of Haematology·2025Open Access
Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling
Blood·2025· 2 citedOpen Access
An open-source repository-based tool for quality control of imaging protocol compliance: demonstration in a multicentre MRI study
British Journal of Radiology·2025· 1 citedOpen Access
Risk adapted therapy for newly diagnosed multiple myeloma delivered through local cytogenetic laboratories in a National Clinical Trial: UKMRA RADAR study
eJHaem·2025· 2 citedOpen Access
Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS
Blood·2024· 14 citedOpen Access
A repository-integrated tool for monitoring imaging protocol compliance in a multi-centre whole-body MRI myeloma study
Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition·2024
A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data
Blood·2024Open Access
Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial
Blood·2024Open Access
Belantamab Mafodotin Plus Cyclophosphamide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Interim Results from the UK Myeloma Research Alliance Prommise Clinical Trial
Blood·2024Open Access
Final Analysis of the Randomised UK MRA Myeloma XI+ Trial Examining Krdc (carfilzomib, lenalidomide, dexamethasone and cyclophosphamide) As Induction Therapy for Newly Diagnosed Multiple Myeloma Patients
Blood·2024Open Access
MRD and Molecular Risk Status Help to Define Optimal Maintenance Delivery Strategies after ASCT: Long Term Outcomes of the UK MRA Myeloma XI Trial Comparing Lenalidomide to Observation
Blood·2024· 2 cited
Optimising the Duration of Therapy for Newly Diagnosed Transplant Ineligible Patients - Analysis of Long Term Follow up Data from the UK MRA Myeloma XI Trial
Blood·2024· 1 citedOpen Access
IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial
Blood·2024· 8 cited
Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome - Long-Term Follow-up of the Ukmra Optimum/Muknine Trial
Blood·2024· 2 citedOpen Access
page 1 of 10Next →

Frequent Co-authors

Faith E. Davies(31), Gareth J. Morgan(31), Gordon Cook(23), Martin Kaiser(23), Graham Jackson(22), Roger G. Owen(22), Mark T. Drayson(21), David A. Cairns(20), Walter M. Gregory(19), Charlotte Pawlyn(16), John R Jones(9), Jindriska Lindsay(8), Kevin Boyd(8), Brian A. Walker(7), Anna Hockaday(7), Bhuvan Kishore(7), Meletios Α. Dimopoulos(6), Alina Striha(6), Corinne Collett(6), Mamta Garg(6)